Neuland Labs.

Which are the latest news on Neuland Labs.?

How big is Neuland Labs.?

As of 10th June, Neuland Laboratories Ltd has a market capitalization of 21,913.00 Cr, with net sales of 2022.98 Cr and a net profit of 363.99 Cr reported in the latest four quarters.

As of 10th June, Neuland Laboratories Ltd has a market capitalization of 21,913.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Neuland Laboratories Ltd reported net sales of 2022.98 Cr and a net profit of 363.99 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing shareholder's funds of 1,524.81 Cr and total assets of 2,179.88 Cr.

Who are in the management team of Neuland Labs.?

The management team of Neuland Labs includes D R Rao (Executive Chairman), D Sucheth Rao (Vice Chairman & CEO), D Saharsh Rao (Vice Chairman & Managing Director), and Sarada Bhamidipati (Company Secretary & Compliance Officer), along with several independent directors. This team combines extensive experience and expertise in the industry.

The management team of Neuland Labs includes the following key members:<BR><BR>1. **D R Rao** - Executive Chairman<BR>2. **D Sucheth Rao** - Vice Chairman & CEO<BR>3. **D Saharsh Rao** - Vice Chairman & Managing Director<BR>4. **Sarada Bhamidipati** - Company Secretary & Compliance Officer<BR><BR>Additionally, the Board of Directors features several independent directors, including:<BR><BR>- **H Dhanrajgir**<BR>- **P V Maiya**<BR>- **Christopher M Cimarusti**<BR>- **Bharati Rao**<BR>- **Nirmala Murthy**<BR>- **Homi Rustam Khusrokhan**<BR>- **Prasad R Menon**<BR>- **Sugata Sircar**<BR>- **Pallavi Joshi Bakhru**<BR><BR>This diverse team brings a wealth of experience and expertise to Neuland Labs.

Who are the peers of the Neuland Labs.?

Peers of Neuland Labs include Emcure Pharma, Wockhardt, Acutaas Chemical, Sai Life, Piramal Pharma, Astrazeneca Pharma, Pfizer, OneSource Specialty, and ERIS Lifescience. Neuland Labs shows good management risk and growth, with a 1-year return of 24.65%, outperforming Piramal Pharma's -19.58%.

Peers: The peers of Neuland Labs. are Emcure Pharma, Wockhardt, Acutaas Chemical, Sai Life, Piramal Pharma, Astrazeneca Phar, Pfizer, OneSource Speci., and ERIS Lifescience.<BR><BR>Quality Snapshot: Excellent management risk is observed at Acutaas Chemical, Astrazeneca Phar, and ERIS Lifescience, while Good management risk is found at Emcure Pharma, Neuland Labs., Pfizer, and the rest. Average management risk is present at Wockhardt and Sai Life, while Below Average management risk is noted at OneSource Speci. For Growth, Excellent growth is seen at Acutaas Chemical and Sai Life, while Good growth is observed at Emcure Pharma, Neuland Labs., and Piramal Pharma, with Average growth at Wockhardt and Pfizer, and Below Average growth at Astrazeneca Phar. Capital Structure ratings show Excellent at Acutaas Chemical, Neuland Labs., and Astrazeneca Phar, Good at Emcure Pharma and ERIS Lifescience, while Below Average is noted at Wockhardt and Piramal Pharma.<BR><BR>Return Snapshot: Acutaas Chemical has the highest 1-year return at 186.21%, while Piramal Pharma has the lowest at -19.58%. Neuland Labs.'s 1-year return of 24.65% is significantly higher than Piramal Pharma's. Additionally, the six-month returns are negative for Piramal Pharma, Astrazeneca Phar, and OneSource Speci.

Why is Neuland Laboratories Ltd falling/rising?

As of 11-Jun, Neuland Laboratories Ltd's stock price is at 16,952.25, showing a slight rise but has underperformed recently with a 1.73% decline over the last two days. Despite short-term challenges, the stock has strong long-term growth prospects, evidenced by an 11.60% year-to-date increase and robust fundamentals.

As of 11-Jun, Neuland Laboratories Ltd's stock price is experiencing a slight rise, currently at 16,952.25, with a change of 19.6 (0.12%) upwards. However, it is important to note that the stock has been underperforming in the short term, having fallen consecutively for the last two days with a total decline of -1.73%. This recent downturn is compounded by a significant drop in investor participation, as evidenced by a 49.68% decrease in delivery volume compared to the 5-day average.<BR><BR>Despite these short-term challenges, the stock has shown strong performance over longer periods, with a year-to-date increase of 11.60% and a remarkable 503.95% rise over the past three years. The company's fundamentals remain robust, highlighted by a high return on equity (ROE) of 16.00% and a very low debt-to-equity ratio of 0.07. Furthermore, Neuland Laboratories has demonstrated impressive growth in net profit, which increased by 424.21%, and has consistently outperformed the BSE500 index over the last three years.<BR><BR>The stock's current valuation is considered expensive, trading at a premium compared to its peers, which may contribute to some investor caution. Nevertheless, the high institutional holdings at 36.3% indicate confidence from larger investors, who have increased their stakes by 0.69% over the previous quarter. Overall, while the stock is currently facing short-term pressures, its long-term growth prospects and strong financial performance suggest a positive outlook.

What does Neuland Labs. do?

Neuland Laboratories Ltd manufactures and sells bulk drugs in the Pharmaceuticals & Biotechnology industry, with a market cap of INR 21,913 Cr. As of March 2026, it reported net sales of 776 Cr and a net profit of 213 Cr.

Overview:<BR>Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs within the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>Incorporated on January 7, 1984, Neuland Laboratories Ltd was promoted by Davuluri Sucheth Rao. The company underwent a significant change when Neuland Drugs & Pharmaceuticals Pvt. Ltd., which was established by the same promoters to manufacture bulk drugs, merged with Neuland Laboratories effective from April 1992. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 776 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 213 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 21,913 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 60.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.07%<BR>- Debt Equity: -0.03<BR>- Return on Equity: 19.42%<BR>- Price to Book: 11.74<BR><BR>Contact Details:<BR>Address: 11 Th Floor Phoenix IVY Buildi, Plot No 573A-III Road No 82 Hyderabad Telangana : 500035<BR>Tel: 91-40-30211600<BR>Email: ir@neulandlabs.com<BR>Website: http://www.neulandlabs.com

Should I buy, sell or hold Neuland Laboratories Ltd?

Are Neuland Laboratories Ltd latest results good or bad?

Neuland Laboratories Ltd's latest Q4 FY26 results are impressive, with a net profit increase of 424.21% quarter-on-quarter and 664.72% year-on-year, alongside significant revenue growth. However, the annual results show a decline in revenue and profit, indicating potential challenges in sustaining this strong performance.

Neuland Laboratories Ltd's latest results for Q4 FY26 are quite impressive. The company reported a net profit of ₹212.67 crores, which marks a staggering increase of 424.21% quarter-on-quarter and 664.72% year-on-year. Additionally, revenue surged to ₹776.25 crores, reflecting a growth of 76.54% from the previous quarter and 136.40% compared to the same quarter last year. <BR><BR>The operating margin, excluding other income, improved significantly to 39.59%, up from 17.54% in the prior quarter, indicating strong operational efficiency. The profit after tax margin also rose to 27.40%, showcasing the company's ability to convert revenue growth into substantial profit.<BR><BR>However, while the quarterly performance is exceptional, the annual results present a more mixed picture. For the full year FY25, Neuland Laboratories experienced a decline in revenue by 5.3% and a 13.33% drop in net profit compared to FY24. This suggests that while the recent quarter was outstanding, there are underlying challenges in sustaining such performance consistently.<BR><BR>Overall, the latest quarterly results are certainly good, demonstrating a strong turnaround and operational strength, but the annual decline raises questions about the sustainability of this performance moving forward.

How has been the historical performance of Neuland Labs.?

Neuland Labs experienced fluctuating financial performance, with net sales and operating income peaking at 1,558.58 Cr in March 2024 before declining to 1,476.84 Cr in March 2025, while profit metrics also decreased. However, total assets and cash flow from operating activities improved during the same period.

Answer:<BR>The historical performance of Neuland Labs shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Neuland Labs' net sales peaked at 1,558.58 Cr in March 2024 but declined to 1,476.84 Cr by March 2025. The total operating income followed a similar pattern, reaching 1,558.58 Cr in March 2024 before dropping to 1,476.84 Cr in March 2025. Raw material costs increased from 360.44 Cr in March 2019 to 574.81 Cr in March 2025, while employee costs rose from 110.46 Cr in March 2019 to 272.00 Cr in March 2025. Operating profit (PBDIT) saw a decline from 475.13 Cr in March 2024 to 343.78 Cr in March 2025, with a corresponding decrease in profit before tax from 401.44 Cr to 346.33 Cr. Profit after tax also fell from 300.08 Cr in March 2024 to 260.11 Cr in March 2025. The company's total assets increased significantly from 1,230.98 Cr in March 2020 to 2,179.88 Cr in March 2025, while total liabilities rose from 1,230.98 Cr to 2,179.88 Cr in the same period. Cash flow from operating activities improved from 261.00 Cr in March 2024 to 317.00 Cr in March 2025, contributing to a net cash inflow of 44.00 Cr by March 2025.

Is Neuland Labs. technically bullish or bearish?

As of October 8, 2025, the trend has shifted to bullish with strong indicators like the weekly MACD and Bollinger Bands supporting this view, although caution is advised due to mildly bearish monthly MACD and KST signals.

As of 8 October 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish. Daily moving averages also confirm a bullish trend. However, the monthly MACD and KST are mildly bearish, indicating some caution. Overall, the strength of the bullish trend is reinforced by the positive returns over various periods, particularly the impressive 3-year and 5-year returns compared to the Sensex.

Is Neuland Labs. overvalued or undervalued?

As of November 8, 2023, Neuland Labs is considered very expensive with a PE ratio of 83.55, significantly higher than its peers, indicating potential overvaluation despite a strong 1-year stock return of 105.28%.

As of 8 November 2023, Neuland Labs' valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a PE ratio of 83.55, a Price to Book Value of 10.97, and an EV to EBITDA ratio of 51.10. These metrics suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Neuland Labs stands out with a notably higher PE ratio than Sun Pharma, which has a PE of 35.25, and Divi's Lab at 79.33. Other peers like Cipla and Dr. Reddy's Labs exhibit much lower valuations, with PE ratios of 22.99 and 19.49, respectively. Despite recent strong stock performance, with a 1-year return of 105.28% compared to the Sensex's 7.58%, the elevated valuation metrics indicate that Neuland Labs may not sustain its current price levels in the long term.

Who are the top shareholders of the Neuland Labs.?

The top shareholders of Neuland Labs include the Davuluri Ownership Trust with 25.98%, individual investors with 25.86%, and 189 Foreign Institutional Investors holding 22.11%. The highest public shareholder is Malabar India Fund Limited at 5.76%, with no pledged promoter holdings reported.

The top shareholders of Neuland Labs include the Davuluri Ownership Trust, which holds the largest stake at 25.98%. Additionally, individual investors collectively own 25.86% of the company. Among institutional investors, 189 Foreign Institutional Investors (FIIs) hold 22.11%, while mutual funds are represented by 23 schemes with a combined holding of 7.43%. The highest public shareholder is Malabar India Fund Limited, with a stake of 5.76%. There are no pledged promoter holdings reported.

When is the next results date for Neuland Labs.?

No Upcoming Board Meetings

Has Neuland Labs. declared dividend?

Yes, Neuland Laboratories Ltd has declared a dividend of 140% (₹14 per share) with an ex-date of July 12, 2024. While recent returns have been volatile, the company has shown substantial long-term growth, with a total return of 3148.39% over the past five years.

Neuland Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 140%<BR>- Amount per share: 14<BR>- Ex-date: 12 Jul 24<BR><BR>Dividend Yield: 0.12%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -25.58%, with a dividend return of 0%, resulting in a total return of -25.58%.<BR><BR>Over the past year, the price return was 112.28%, the dividend return was 0.22%, leading to a total return of 112.5%.<BR><BR>In the 2-year period, the price return was 347.43%, with a dividend return of 0.82%, culminating in a total return of 348.25%.<BR><BR>For the 3-year period, the price return was 1133.21%, the dividend return was 2.76%, resulting in a total return of 1135.97%.<BR><BR>In the last 4 years, the price return was 522.76%, with a dividend return of 1.61%, leading to a total return of 524.37%.<BR><BR>Over the past 5 years, the price return was 3142.13%, with a dividend return of 6.26%, resulting in a total return of 3148.39%.<BR><BR>Overall, Neuland Laboratories Ltd has declared a significant dividend, and while the recent returns have shown volatility, particularly in the short term, the longer-term performance indicates substantial growth in total returns, driven largely by price appreciation.